← FDA DRUG APPROVALS

FDA ANDA · ANDA075082

METHADONE HYDROCHLORIDE

Sponsor: VISTAPHARM LLC

APPLICATION
ANDA075082
TYPE
ANDA
ORIGINAL APPROVAL
1998-03-25
LATEST ACTION
2024-08-27
ROUTE
ORAL
DOSAGE FORM
TABLET, FOR SUSPENSION
MARKETING STATUS
Prescription

Products

METHADONE HYDROCHLORIDEPrescription
METHADONE HYDROCHLORIDE 40MG · TABLET, FOR SUSPENSION · ORAL

Approval history

2024-08-27Labeling · Supplement 17 · standardAP
2024-08-27Labeling · Supplement 15 · standardAP
2024-08-27Labeling · Supplement 9 · standardAP
2024-08-27Labeling · Supplement 7 · standardAP
2024-08-27Labeling · Supplement 14 · standardAP
2018-09-18REMS · Supplement 8AP
2015-08-17Labeling · Supplement 6 · standardAP
2007-12-14Labeling · Supplement 5AP
2000-02-02Manufacturing (CMC) · Supplement 2AP
1998-08-25Labeling · Supplement 1AP
1998-03-25OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →